Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT07369076
- Testing
- NB-4746 High dose, NB-4746 Low dose, NB-4746 (Dose TBD)
- Where
- 12 sites in Australia, Canada and 2 more
- Volunteers
- 80 people
- Sponsor
- Nura Bio
Amyotrophic Lateral Sclerosis, Home Mechanical Ventilation
Development in Home Mechanical Ventilation for Patient With Amyotrophic Lateral Sclerosis.
The aims of the study are to calculate the positive predictive value (PPV) of the codes for home mechanical noninvasive and invasive ventilation in patients with Amyotrophic lateral sclerosis in Denmark, and to describe the…
- Trial name
- NCT07819890
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Amyotrophic Lateral Sclerosis, ALS
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
69 subjects with ALS will be enrolled in the study and randomized at a 2:1 ratio to receive the study drug or placebo tablets. Randomization sequences will be in random block sizes and stratified for ENCALS risk category [high…
- Trial name
- PARADIGM (NCT05357950)
- Testing
- PrimeC
- Where
- 4 sites in Canada, Israel and 1 more
- Volunteers
- 69 people
- Sponsor
- NeuroSense Therapeutics Ltd.
Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy
Study of ALS Reversals 4: LifeTime Exposures
Hypothesis: There exists patients who have met ALS or PMA diagnostic criteria and subsequently experienced robust and sustained improvement, i.e.
- Conditions
- Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy, Motor Neuron Disease
- Trial name
- StARLiTE (NCT03706391)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis
Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway
The study examines if titration of Non-Invasive mechanical ventilation (NIV) settings during ongoing laryngoscopic visualization can improve the compliance of NIV in subjects with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03887338
- Testing
- Transnasal Fiberoptic Laryngoscopy
- Where
- 2 sites in Norway, Portugal
- Volunteers
- 60 people
- Sponsor
- Tiina Maarit Andersen
Amyotrophic Lateral Sclerosis
Aerobic Exercise Training in Amyotrophic Lateral Sclerosis
The purpose of this study is to compare the safety and the effects of moderate-intensity aerobic endurance training to those of an usual physical therapy intervention on exercise capacity and quality of life in patients with…
- Trial name
- ENDURANCE (NCT01650818)
- Testing
- Aerobic exercise training, Standard physical therapy (Stretching/Range-of-motion)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Salvatore Maugeri
Amyotrophic Lateral Slerosis
Inspiratory Muscle Training in Amiotrophyc Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) progressively damages the nerve cells responsible for voluntary muscle movement. Over time, this leads to weakness in different muscles such as those used for movement or breathing.
- Trial name
- IMT4LAS (NCT07413718)
- Testing
- Inspiratory muscle training
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- University Ramon Llull
Amyotrophic Lateral Sclerosis
DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease
In response to oxidative stress, cells activate the Nrf-2 pathway, which induces translation of its target genes and corresponding proteins involved in the antioxidant response.
- Trial name
- DIAGALS (NCT06230562)
- Testing
- Blood sample
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis
Dysphagia, QoL and Attitudes Towards PEG in ALS Patients
In Amyotrophic Lateral Sclerosis, dysphagia has a high incidence. With deterioration of swallowing function, percutaneous endoscopic gastrostomy (PEG) tube is recommended to ensure sufficient and safe oral intake.
- Trial name
- ALSDPEG (NCT05336760)
- Testing
- Iowa Oral Performance Instrument (IOPI), Mann Assessment of Swallowing Ability (MASA), Fiberoptic Endoscopic Evaluation of Swallowing
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- University Rehabilitation Institute, Republic of Slovenia
Amyotrophic Lateral Sclerosis, Psychological Stress
Psychological Therapy for Patients With ALS
Amyotrophic lateral sclerosis (ALS) is a disease that is inevitably fatal. To be diagnosed with a terminal illness such as ALS deeply affects one's personal existence and goes along with significant changes regarding the…
- Trial name
- NCT03975608
- Testing
- Adaptation of "CALM"
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University of Leipzig
Amyotrophic Lateral Sclerosis, ALS
Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis
This study is a follow-up to an earlier study that examined the relationship of This study will examine whether exposure to neurotoxins, such as lead, mercury, solvents, and pesticides, can contribute to amyotrophic lateral…
- Trial name
- NCT00339976
- Where
- United States
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amyotrophic Lateral Sclerosis, Plasmapheresis
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody
- Trial name
- PALATIN (NCT05562960)
- Testing
- Plasmapheresis
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Amyotrophic Lateral Sclerosis
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
Primary objectives: To assess the safety and tolerability of ascending doses of NP001 compared to placebo in subjects with ALS. Secondary objective: To explore the effects of NP001 on biomarkers potentially relevant to ALS.
- Trial name
- NCT01091142
- Testing
- NP001
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate
There is a lack of prospective and population-based epidemiological data on amyotrophic lateral sclerosis in Germany so far. The purpose of this registry is to investigate the incidence, course and phenotypic variety of ALS in…
- Trial name
- NCT01955369
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Klinikum Ludwigshafen
Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known…
- Trial name
- NCT07259980
- Testing
- Tofersen
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)
This research is being done to see if the ketogenic diet (which is high in fat and low in carbohydrates) is safe and tolerable in amyotrophic lateral sclerosis (ALS) patients who are fed through a gastrostomy tube.
- Trial name
- NCT01016522
- Testing
- KetoCal
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Anarthria, Dysarthria
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to…
- Conditions
- Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries
- Trial name
- BG-Speech-02 (NCT06094205)
- Testing
- BrainGate Neural Interface System
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Leigh R. Hochberg, MD, PhD.
Amyotrophic Lateral Sclerosis
Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to progressive muscle weakness and functional decline.
- Trial name
- NCT07467746
- Testing
- C. cicadae, Control
- Volunteers
- 84 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a phase II study to determine the safety and tolerability of ILB®, a type of low molecular weight dextran sulfate, in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- ALS (NCT03705390)
- Testing
- ILB®
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- University of Birmingham
Amyotrophic Lateral Sclerosis
Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting
In patients with amyotrophic lateral sclerosis (ALS), non-invasive mechanical ventilation (NIV) is usually initiated in an in-hospital regime.
- Trial name
- NCT02759003
- Testing
- Nightime NIV initiation
- Volunteers
- 50 people
- Sponsor
- Fondazione Salvatore Maugeri